人胚脑与脊髓神经干细胞体外生物学特性的差异

目的:探讨人胚脑源性神经干细胞和脊髓源性神经干细胞的体外培养和分化的差异。方法:从人胚脑组织和脊髓组织中分离培养神经干细胞,分为EGF组、bFGF组、EGF±bFGF组,在连续传代过程中观察并比较神经干细胞体外培养特性的差异:用血清诱导神经干细胞分化,观察其分化状况的不同。结果:从人胚脑组织分离的细胞在bFGF 单独存在时无法形成神经球,在EGF或EGF±bFGF存在时形成大量具有连续增殖能力的神经球;从人胚脊髓组织分离的细胞在EGF单独存在时无法形成神经球,在bFGF单独存在时只形成少量神经球,在EGF±bFGF存在时形成大量具有连续增殖能力的神经球。同样在EGF±bFGF存在的情况下,脑源性于细胞的增殖速度较快。经血清诱导后,脑组织来源的干细胞分化为NSE阳性细胞数明显多于脊髓组织来源的干细胞,二者之间的差异具有显著性(P<0．05)。结论:脑源性和脊髓源性神经干细胞在生长和分化方面有明显差别:脑源性神经干细胞可在bFGF或EGF士bFGF存在的情况下长期传代,而脊髓源性神经干细胞只能在EGF±bFGF存在的情况下长期传代,脑源性干细胞的增殖能力明显高于脊髓源性干细胞;脑源性干细胞较脊髓源性干细胞更易分化为神经元。     

损伤脊髓匀浆上清对骨髓间充质干细胞分泌髓鞘前脂蛋白、脑源性神经营养因子的影响

背景：损伤脊髓匀浆上清成分复杂,其中不仅存在多种化学物质,而且也存在着多种细胞因子,这些物质能否影响骨髓间充质干细胞的增殖分化和分泌功能还不清楚。 目的：探讨损伤脊髓匀浆上清成分对骨髓间充质干细胞分泌的脑源性神经营养因子和髓鞘前脂蛋白的影响。 方法：贴壁法分离纯化Wistar大鼠骨髓间充质干细胞,稳定传到第3代后,分别用正常和损伤的Wistar大鼠脊髓匀浆上清诱导培养20 d。免疫荧光染色检测神经元特异性烯醇化酶阳性细胞,ELISA法检测培养液内髓鞘前脂蛋白、脑源性神经营养因子的含量,即时定量-PCR检测髓鞘前脂蛋白mRNA、脑源性神经营养因子mRNA水平。 结果与结论：损伤脊髓匀浆上清液诱导培养骨髓间充质干细胞后,神经元特异性烯醇化酶阳性细胞率和培养液内脑源性神经营养因子、髓鞘前脂蛋白的含量在各个时间点均较正常脊髓匀浆上清液对骨髓间充质干细胞培养组高。提示,损伤的脊髓匀浆上清液能够诱导骨髓间充质干细胞分泌脑源性神经营养因子、髓鞘前脂蛋白,有利于向神经细胞方向分化。     

胚胎小鼠脊髓源性与纹状体源性神经干细胞的培养及分化特点

目的 探讨小鼠脊髓源性神经干细胞与纹状体源性神经干细胞的分离培养方法 及增殖特点,比较两种来源的神经干细胞发育时期上的异同,寻找更有利于脊髓损伤修复的种子细胞.方法 利用显微解剖、无血清培养和单细胞克隆技术在孕14 d小鼠的胎鼠的脊髓及纹状体中分离培养具有单细胞克隆能力的细胞,免疫荧光染色检测克隆细胞的神经巢蛋白(nestin)抗原和诱导分化后特异性成熟神经细胞抗原的表达,并比较两种来源的干细胞在培养及分化方向上的异同点.结果从胎鼠的脊髓和纹状体中成功分离出神经干细胞.两种来源的干细胞均具有连续克隆能力可传代培养,表达nestin.脊髓血清诱导分化后脊髓源性神经干细胞β-tubulinⅢ阳性细胞(13.5±0.8)较纹状体源性神经干细胞(17.4±1.1)减少,而nestin、GFAP阳性细胞明显增多(45.7±0.3vs 39.2±1.2;25.2±1.3 vs 18.8±0.9),差异均有统计学意义(P<0.05). 结论 依据细胞增殖特点和分化结果的区别,证实纹状体源性神经干细胞更适合用于移植修复脊髓损伤.     

人胚脊髓神经干细胞的分离培养和鉴定

目的:探讨人胚脊髓神经干细胞的体外培养和分化的方法,观察其增殖和分化特点。方法:利用无血清培养和单细胞克隆技术从人胚脊髓组织中分离培养出神经干细胞并用血清诱导其分化,应用免疫荧光细胞化学技术对培养细胞及其分化细胞进行鉴定。结果:从人胚脊髓组织分离的细胞在EGF单独存在时无法形成神经球,在bFGF单独存在时只形成少量神经球,在EGF和bFGF共同存在时形成大量具有连续增殖能力的神经球,表达神经干细胞的标志物Nestin,经血清诱导后分化为神经元、星形胶质细胞和少突胶质细胞并表达特异性抗原NSE、GFAP和CNP。结论:在体外培养条件下可从人胚脊髓组织中培养出神经干细胞,它可为神经干细胞的基础研究和临床应用提供材料。     

小神经球体外和脊髓内移植促进神经干细胞向神经元分化

目的 研究神经干细胞小神经球体外和脊髓内移植后的分化。方法 从20周人胚胎分离神经干细胞进行鉴定,经培养成小神经球体外诱导分化;成年雌性Wistar大鼠于T11水平行椎板切开术并横切腰段脊髓,立体定向注射细胞50000个进入两侧脊髓断端中线的3个部位（薄束、楔束及皮质脊髓束）。移植3个月后利用双标免疫荧光观察神经干细胞的分化情况。结果 小神经球实验组在体外和受伤大鼠脊髓内诱导分化的神经元高于单细胞悬液对照组,前者有显著差异．后者有极显著差异。小神经球脊髓移植后细胞的存活率明显增加,与对照组相比有显著差异（P〈0．05）。结论 小神经球移植增加细胞的存活率,分化的神经元数量增加,应当成为较好的脊髓神经干细胞移植方式。     

间充质干细胞移植修复脊髓损伤的研究现状

骨髓间充质干细胞在体外没有外界因素作用下连续传50代仍可保持原来的特性,亦可在一些条件的诱导下分化成神经细胞。实验研究表明,间充质干细胞移植能促进脊髓损伤的神经结构修复及神经功能恢复,其机制可能与替代作用、营养作用、诱导作用、桥接作用等有关。携带外源功能基因的骨髓间充质干细胞移植到体内存活、迁徙、分化并基因表达脑源性生长因子、神经生长因子等细胞因子,明显促进脊髓损伤的恢复,成为了新的研究热点。随着对间充质干细胞的生物学特性进一步深入研究,一些未解决的问题将会逐步得到解决,为脊髓损伤和其他神经系统疾病的患者带来新的希望。     

脂肪干细胞源性神经干细胞克隆球的电镜观察

目的观察脂肪干细胞(ADSCs)源性神经干细胞克隆球的超微结构形态。方法原代培养大鼠ADSCs,向神经干细胞诱导分化,分化为克隆球后,免疫荧光鉴定其Nestin表达,透射电子显微镜观察克隆球超微结构形态。结果大鼠ADSCs可诱导分化为细胞克隆球,其Nestin表达阳性,超微结构与原代培养的神经干细胞克隆球的超微结构相似。结论 ADSCs经诱导分化后形成的克隆球具有神经干细胞的特征。     

脊髓来源神经干细胞分离培养及向雪旺氏细胞的诱导分化

目的 探讨新生大鼠脊髓来源神经干细胞(NSCs)的分离培养及在体外一定条件下向周围神经雪旺氏细胞分化的可行性. 方法 分离新生大鼠的脊髓组织,在含有B27(终浓度1%)、碱性成纤维细胞生长因子(bFGF)和表皮生长因子(EGF)(终浓度均为20 μg/L)培养基中分离培养出NSCs.用复合诱导因子(10%FBS+5 μmol/L血小板凝集抑制剂+10 ng/mL bFGF+5 ng/mE血小板源性生长因子)在体外诱导NSCs分化为雪旺氏细胞.免疫荧光细胞化学方法[一抗为p75、S-100、神经胶质纤维酸性蛋白(GFAP)]鉴定体外诱导分化结果.结果 培养的新生大鼠脊髓组织细胞nestin染色表达阳性;分离培养的大鼠脊髓来源NSCs经诱导分化后形态类似雪旺氏细胞,免疫荧光细胞化学方法显示诱导后细胞表达雪旺氏细胞的表面标志,GFAP、S-100和P75表达阳性.结论 新生大鼠脊髓来源NSCs可以在体外诱导分化为雪旺氏细胞.     

甲基强的松龙和神经干细胞移植联合治疗大鼠脊髓损伤

目的：观察甲基强的松龙和神经干细胞移植对大鼠脊髓损伤后神经结构修复和功能恢复的治疗作用并探讨其作用机制。方法：制备大鼠胸10脊髓损伤模型，体外培养、诱导分化大鼠神经干细胞，定量评价甲基强的松龙和神经干细胞移植对脊髓损伤后神经结构修复和功能恢复的影响。结果：与对照组相比，移植组明显地增强了生长相关蛋白（GAP－43）mRNA的表达，促进了乙酰胆碱转移酶（ChAT)阳性脊髓运动神经元的再生、神经结构的修复和下肢运动功能的恢复（P＜0．05）。结论：甲基强的松龙和神经干细胞移植通过增强GAP－43 mRNA的表达、运动神经元的再生而促进了脊髓损伤后神经结构的修复和功能的恢复，是急性脊髓损伤的一种有效的治疗方案。     

大鼠骨髓间充质干细胞源性神经元促进脊髓横断性损伤的神经功能恢复

目的探讨干细胞治疗外伤性脊髓损伤的策略。方法体外分离纯化成年SD大鼠骨髓MSCs,并在体外培养过程中加入麝香多肽(Musk-1)将其诱导分化为神经前体细胞,再定向将神经前体细胞植入经显微外科手术建立的大鼠横断性脊髓损伤病灶中。结果与对照组大鼠相比,植入的rMSCs源性神经元可明显促进脊髓损伤后的神经功能恢复(P<0．05;有效观察期90 d)。组织学和免疫细胞组化分析进一步证实了植入rMSCs源性神经元在移植区域大量成活,并向损伤区域四周的邻近组织迁移约6 mm。荧光金逆行追踪分析显示在大鼠脊髓头侧、中脑红核和大脑感觉运动皮层等区域均可检测到荧光金标记阳性的运动神经元,推测脊髓损伤侧的皮层脊髓束发生了再生并穿越横断性病灶达到了脊髓尾侧。结论作为干细胞替代治疗的新策略,rMSCs源性神经元可在横断性脊髓损伤病灶中成活、迁移、整合,以及具备修补脊髓功能的潜在可能性。     

Neural stem cell, as a source of graft material for transplantation in neuronal disease

Self-renewing and multipotent neural stem cells are present in the adult human brain. We successfully harvested neural stem cells from mice and humans using misexpressed EGFP proteins under the control of the nestin second intron enhancer. High-level EGFP expressors derived from mouse embryos included a distinct subpopulation of cells that were self-renewable and multipotent. Further, we obtained that neural progenitor cells from rat fetal spinal cords using a neurosphere technique, and demonstrated their ability to divide and differentiate into neurons in vivo, where they were integrated into the host tissue in the injured rat spinal cord with resultant behavioral improvement of the recipient rat. We also harvested tyrosine hydroxylase-positive neurons from a transgenic mouse expressing GFP under the control of the tyrosine hydroxylase promoter, and successfully transplanted them into the striatum of rats with parkinsonism with marked improvement of the neurological symptoms. Since neural stem cells can adapt well in the host CNS, studies should focus on their application as a vector in gene therapy and on the introduction in vivo or ex vivo of genes to control their proliferation and differentiation. Neural stem cells are a potential, useful source for developing new therapy for CNS disorders.     

Induced pluripotent stem cell-derived neural stem cell therapies for spinal cord injury

The greatest challenge to successful treatment of spinal cord injury is the limited regenerative capacity of the central nervous system and its inability to replace lost neurons and severed axons following injury. Neural stem cell grafts derived from fetal central nervous system tissue or embryonic stem cells have shown therapeutic promise by differentiation into neurons and glia that have the potential to form functional neuronal relays across injured spinal cord segments. However, implementation of fetal-derived or embryonic stem cell-derived neural stem cell therapies for patients with spinal cord injury raises ethical concerns. Induced pluripotent stem cells can be generated from adult somatic cells and differentiated into neural stem cells suitable for therapeutic use, thereby providing an ethical source of implantable cells that can be made in an autologous fashion to avoid problems of immune rejection. This review discusses the therapeutic potential of human induced pluripotent stem cell-derived neural stem cell transplantation for treatment of spinal cord injury, as well as addressing potential mechanisms, future perspectives and challenges.     

The developing human spinal cord contains distinct populations of neural precursors

It is becoming apparent that neural stem cells display some differences in their behaviour depending on the region of the CNS they originate from and on whether they are derived from embryonic or adult tissue. Whereas much work has focused on brain neural stem cells, less attention has been paid to spinal cord neural precursors, particularly in the developing human embryo. We briefly review here some of our work which points at some similarities between neural precursors in developing human spinal cords and in animals which can regenerate their spinal cord (e.g. tailed amphibians), and at differences in the properties of human neural precursors with spinal cord development. Altogether these studies suggest the existence of dynamic neural stem cell populations within the developing spinal cord. They also support the notion that thorough characterization of neural stem cells under different culture conditions and analysis of how these may affect their differentiation in vivo after grafting into different injury models is imperative if we are to develop effective cell therapy strategies for spinal cord injury and diseases.     

不同来源成体神经干细胞促进大鼠脊髓损伤功能修复的比较研究

目的 评价大脑、骨髓和脂肪组织3种不同来源的神经干细胞对大鼠脊髓挫伤的治疗效果.方法 选取来源于同一大鼠成体中大脑、骨髓和脂肪的3个部位的组织,分离、诱导分化为不同来源的神经干细胞;应用自由落体损伤模型装置造成大鼠脊髓挫伤.将不同来源的神经干细胞分别移植入大鼠脊髓损伤部位,通过BBB评分比较修复脊髓损伤功能的效果,应用免疫荧光染色检测不同移植细胞在损伤脊髓中的存活、分布、迁移的情况.另设假手术对照组和生理盐水对照组.结果 与假手术对照组和生理盐水对照组比较,3个细胞处理组BBB评分在2～8周开始增加,9周以后更加明显,差异开始有统计学意义(P<0.05).在移植后1周和4周,细胞移植组中脑源性神经干细胞(SVZ-NSs)组Brdu/nestin+>神经元存活的数目明显高于其他2组.但差异没有统计学意义(P>0.05);到了第8周,3组均仅有少量Brdu/nestin+>细胞存活,相互之间比较差异无统计学意义(P>0.05).结论 植入来源于大脑、骨髓和脂肪组织的神经干细胞都可以在一定程度上提高脊髓损伤后运动功能恢复,但SVZ-NSs组的脊髓损伤大鼠运动功能恢复要比脂肪来源的神经干细胞(AD-NSs)组及骨髓来源的神经干细胞(BM-NSs)组更好.AD-NSs由于来源广泛和强有力的增殖能力,相比其他来源的神经干细胞,可能是更好的选择.     

菲立磁标记兔BMSCs自体移植脊髓后的核磁共振活体示踪及形态学研究

目的通过观察菲立磁标记兔骨髓源性神经干细胞(BMSCs)自体移植脊髓后的核磁共振活体示踪及形态,期待找到一种应用非侵袭性方法来识别、跟踪BMSCs的存活状态及与宿主组织整合情况的方法。方法无菌条件下股骨取骨髓,梯度密度离心法分离获取兔骨髓基质细胞;使用“Feridex-多聚赖氨酸复合物(FE-PLL)”标记骨髓基质细胞,采用普鲁士兰染色和台盼蓝排除实验等方法鉴定FE-PLL标记兔骨髓基质细胞的效率和细胞的活力;体外标记的细胞自体脊髓移植,磁共振、免疫组织化学染色和透射电镜检查。结果普鲁士蓝染色显示FE-PLL标记骨髓基质细胞胞质内出现细小的蓝色铁颗粒;与正常未标记的细胞相比较,FE-PLL标记对骨髓基质细胞的活力、增殖和分化等能力没有明显的影响;经菲立磁标记的兔BMSCs自体脊髓移植后,可在核磁共振上活体示踪。结论菲立磁与核磁共振联合可无创性活体标记检测移植的神经干细胞基本的存在部位、存在方式及其一些生物学特性,可以用来活体示踪移植的BMSCs。     

Brain and spinal cord affected by amyotrophic lateral sclerosis induce differential growth factors expression in rat mesenchymal and neural stem cells

C. Nicaise, D. Mitrecic and R. Pochet (2011) Neuropathology and Applied Neurobiology 37, 179–188
Brain and spinal cord affected by amyotrophic lateral sclerosis induce differential growth factors expression in rat mesenchymal and neural stem cells Stem cell research raises hopes for incurable neurodegenerative diseases. In amyotrophic lateral sclerosis (ALS), affecting the motoneurones of the central nervous system (CNS), stem cell‐based therapy aims to replace dying host motoneurones by transplantation of cells in disease‐affected regions. Moreover, transplanted stem cells can serve as a source of trophic factors providing neuroprotection, slowing down neuronal degeneration and disease progression. Aim: To determine the profile of seven trophic factors expressed by mesenchymal stem cells (MSC) and neural stem cells (NSC) upon stimulation with CNS protein extracts from SOD1‐linked ALS rat model. Methods: Culture of rat MSC, NSC and fibroblasts were incubated with brain and spinal cord extracts from SOD1(G93A) transgenic rats and mRNA expression of seven growth factors was measured by quantitative PCR. Results: MSC, NSC and fibroblasts exhibited different expression patterns. Nerve growth factor and brain‐derived neurotropic factor were significantly upregulated in both NSC and MSC cultures upon stimulation with SOD1(G93A) CNS extracts. Fibroblast growth factor 2, insulin‐like growth factor and glial‐derived neurotropic factor were upregulated in NSC, while the same factors were downregulated in MSC. Vascular endothelial growth factor A upregulation was restricted to MSC and fibroblasts. Surprisingly, SOD1(G93A) spinal cord, but not the brain extract, upregulated brain‐derived neurotropic factor in MSC and glial‐derived neurotropic factor in NSC. Conclusions: These results suggest that inherent characteristics of different stem cell populations define their healing potential and raise the concept of ALS environment in stem cell transplantation.     

Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats

Neural progenitor cells, including neural stem cells, are a potential expandable source of graft material for transplantation aimed at repairing the damaged CNS. Here we present the first evidence that in vitro-expanded fetus-derived neurosphere cells were able to generate neurons in vivo and improve motor function upon transplantation into an adult rat spinal-cord-contusion injury model. As the source of graft material, we used a neural stem cell-enriched population that was derived from rat embryonic spinal cord (E14.5) and expanded in vitro by neurosphere formation. Nine days after contusion injury, these neurosphere cells were transplanted into adult rat spinal cord at the injury site. Histological analysis 5 weeks after the transplantation showed that mitotic neurogenesis occurred from the transplanted donor progenitor cells within the adult rat spinal cord, a nonneurogenic region; that these donor-derived neurons extended their processes into the host tissues; and that the neurites formed synaptic structures. Furthermore, analysis of motor behavior using a skilled reaching task indicated that the treated rats showed functional recovery. These results indicate that in vitro-expanded neurosphere cells derived from the fetal spinal cord are a potential source for transplantable material for treatment of spinal cord injury.     

Transplantation of erythropoietin gene-modified neural stem cells improves the repair of injured spinal cord

The protective effects of erythropoietin on spinal cord injury have not been well described. Here, the eukaryotic expression plasmid pc DNA3.1 human erythropoietin was transfected into rat neural stem cells cultured in vitro. A rat model of spinal cord injury was established using a free falling object. In the human erythropoietin-neural stem cells group, transfected neural stem cells were injected into the rat subarachnoid cavity, while the neural stem cells group was injected with non-transfected neural stem cells. Dulbecco's modified Eagle's medium/F12 medium was injected into the rats in the spinal cord injury group as a control. At 1–4 weeks post injury, the motor function in the rat lower limbs was best in the human erythropoietin-neural stem cells group, followed by the neural stem cells group, and lastly the spinal cord injury group. At 72 hours, compared with the spinal cord injury group, the apoptotic index and Caspase-3 gene and protein expressions were apparently decreased, and the bcl-2 gene and protein expressions were noticeably increased, in the tissues surrounding the injured region in the human erythropoietin-neural stem cells group. At 4 weeks, the cavities were clearly smaller and the motor and somatosensory evoked potential latencies were remarkably shorter in the human erythropoietin-neural stem cells group and neural stem cells group than those in the spinal cord injury group. These differences were particularly obvious in the human erythropoietin-neural stem cells group. More CM-Dil-positive cells and horseradish peroxidase-positive nerve fibers and larger amplitude motor and somatosensory evoked potentials were found in the human erythropoietin-neural stem cells group and neural stem cells group than in the spinal cord injury group. Again, these differences were particularly obvious in the human erythropoietin-neural stem cells group. These data indicate that transplantation of erythropoietin gene-modified neural stem cells into the subarachnoid cavity to help repair spinal cord injury and promote the recovery of spinal cord function better than neural stem cell transplantation alone. These findings may lead to significant improvements in the clinical treatment of spinal cord injuries.